Current Headlines

  1. Alnylam Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Givosiran For The Treatment Of Acute Hepatic Porphyria
    6/5/2019

    Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced recently the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP)

  2. Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Bardoxolone Methyl For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
    6/5/2019

    Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to bardoxolone methyl (bardoxolone) for the treatment of autosomal dominant polycystic kidney disease (ADPKD)

  3. Abveris And TetraGenetics Announce Antibody Discovery Collaboration
    6/4/2019

    Abveris, Inc., a leader in contract research antibody discovery, recently announced that it has entered into a multi-target agreement with TetraGenetics, Inc. a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders

  4. Researchers Develop Breakthrough Process To Create Cancer-Killing Drugs
    6/4/2019

    A research team at Dartmouth College has developed a new strategy for drug discovery and development that can be used to produce targeted therapies against diseases such as cancer and neurodegeneration, according to a study published in Nature Communications

  5. U.S. FDA Accepts New Drug Application For Triple Combination Tablet For Adults With Type 2 Diabetes
    6/4/2019

    The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release (XR) for the treatment of adults with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced

  6. Reaction Biology Receives Subcontract For Biophysical Drug Discovery
    6/4/2019

    Reaction Biology Corporation ("RBC"), a leading contract research organization providing early stage drug discovery services, announced that it has received a subcontract from Leidos Biomedical Research, Inc., which operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute

  7. Verseon Showcases Candidates For Next-Generation Diabetic Eye Disease Drugs
    6/4/2019

    Verseon presented their oral drug candidates for diabetic macular edema (DME) at this week’s 2019 BIO International Convention in Philadelphia

  8. Atomwise Announces Multi-Year, Multi-Target Agreement With Lilly For AI-Driven Drug Discovery Program
    6/3/2019

    Atomwise Inc. recently announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts

  9. HitGen Enters Into DNA-Encoded Library Based Drug Discovery Research Collaboration With Gilead Sciences
    6/3/2019

    HitGen Inc. recently announced that it has entered into a drug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead

  10. Strateos Combines Transcriptic And 3Scan To Become Premier Drug Discovery Technology Partner For The Pharmaceutical Industry
    6/3/2019

    The boards of Transcriptic and 3Scan have unanimously approved an agreement to merge companies to combine their considerable engineering capabilities in developing automated systems for chemistry, biology, and tissue analysis. The resulting new company is Strateos